AtaiBeckley Inc. Common Stock
Veridion Score
Composite trend over time
Why is ATAI moving today?
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ATAI.
ATAI insider activity
AtaiBeckley Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for ATAI.
ATAI contract awards, year to date.
Public federal awards linked to this ticker.
ATAI lobbying filings, year to date.
Registered lobbying filings matched to AtaiBeckley Inc. Common Stock.